BBI Solutions (BBI), a supplier of immunodiagnostic reagents, has announced the launch of a new Jo-1 human chimeric antibody for use as a calibrator or positive control in assays to diagnose conditions such as connective tissue disease (CTD).
BBI has used cell culture technologies in response to the concerning situation, as hospital visits continue to be dominated by COVID-related cases, leading to a drop in supplies of positive patient materials for certain markers, which are commonly used for calibrators and controls in IVD assays.
Autoantibodies against the aminoacyl-tRNA synthetase Jo-1 can be found in up to 20% of patients with idiopathic inflammatory myopathies (IIM), a sub-form of CTD.¹ Jo-1 is therefore the most prevalent marker found in IIM.
Anti-synthetase autoantibodies, such as Jo-1 autoantibodies, are also strongly associated with interstitial lung disease (ILD) which makes an early diagnosis on a component level even more important.
BBI’s Jo-1 human chimeric monoclonal antibody will help companies which manufacture diagnostic tests provide physicians with the most reliable tests on the market.
Human chimeric monoclonal antibodies can be used as an alternative to characterized disease state plasma. They are produced in transgenic mouse strains in which the sequence for mouse IgG1 Fc region is substituted with the human sequence. After mouse immunization and use of hybridoma technology, antibodies are generated that retain a human constant region required for recognition by the anti-human IgG detection antibody.
Customers in China should purchase through BBI’s China distribution partner BioSun. Customers in the USA and Canada should enquire through Minneapolis based distribution partner Surmodics.
For more information visit BBI Solutions.
References
1. Betteridge et al. Arthritis Research & Therapy 2011, 13:209
